A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 300 participants.

Also called NCT07219602

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 300 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07219602
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Czechia, Netherlands, Slovakia (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT07219602. Randomized; quadruple masking; primary purpose prevention. Start 2025-12-11 (actual); primary completion 2028-03 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome
Acronym
RUBENS
Condition
Lipidemia
Condition
Type 2 Diabetes (T2DM)
Condition
Metabolic Syndrome (MetS)
Intervention (Drug)
obicetrapib 10 mg + ezetimibe 10 mg FDC daily
Intervention (Drug)
Obicetrapib 10 mg
Intervention (Other)
Placebo
Lead sponsor
NewAmsterdam Pharma (class: industry)

Record details

Record id
cardio:ct-nct07219602
Content hash
606aab18eba182a13db6babcc73adffd9b461d6128248f9f91146608603f5e70